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AbstrAct
Aberrant cytoplasmic sequestration has been reported as an alternative mechanism of 
p53 inactivation to mutation in neuroblastoma. We hypothesized that p53 localization 
and function in neuroblastoma is related to differentiation status. Eighty-two untreated and 
24 paired pre and post-chemotherapy neuroblastomas were studied by immunocytochem-
istry for p53, p21WAF1, BAX, Bcl2 and Ki67. Predominantly nuclear p53 was detected 
in undifferentiated neuroblastoma, and both nuclear and cytoplasmic p53 in differen-
tiating neuroblastoma. The nuclear p53 labeling index (LI) correlated with the Ki67 LI 
(r = 0.51, p < 0.001), and weakly with p21WAF1 (r = 0.37), but not with BAX or Bcl2. 
There was a significant reduction in p53, p21WAF1 and Ki67 LI after chemotherapy 
(p < 0.01), an increase in BAX (p < 0.05), but no change in Bcl2. p53 localization and 
function were examined in two p53 wild-type undifferentiated and 9-cis retinoic acid 
differentiated neuroblastoma cell lines. Using immunocytochemistry, immunofluorescence 
and cell fractionation, p53 was found to be predominantly nuclear in both undifferenti-
ated and differentiated cells. Following irradiation, there was upregulation of p53, 
p21WAF1 and MDM2, but less induced PARP and caspase 3 cleavage in differentiated 
cells, suggesting intact p53 transcriptional function, but resistance to apoptosis. p53 
function in undifferentiated and differentiated cells was confirmed by upregulation of 
p21WAF1 and MDM2 following Nutlin-3 treatment. In conclusion, p53 is predominantly 
nuclear and functional in neuroblastoma regardless of differentiation status.
AbbreviAtions
INPC, international neuroblastoma pathology classification; MKI, mitosis karyorrhexis 
index; RA, 9-cis retinoic acid; ICC, immunocytochemistry; IF, immunofluorescence; TBP, 
TATA binding protein; PARP, poly (ADP-ribose) polymerase; LI, labeling index; INC, 
international neuroblastoma classification of differentiation; OS, overall survival; PFS, 
progression free survival 
introduction
Neuroblastoma, an embryonal malignancy derived from precursor cells of the sympa‑
thetic nervous system, is the most common extracranial solid tumor of childhood. Unlike 
improvements in the survival of many other childhood malignancies, neuroblastoma is 
still one of the most difficult childhood cancers to cure, with less than 30% of patients 
with stage 4 disease over one year of age being long term survivors.1
p53, a tumor suppressor gene often referred to as the “guardian of the genome”, is 
the most frequently mutated gene in human cancers, reported to occur in up to 60% of 
adult cancers. Under normal cellular conditions, p53 is maintained at low levels due to 
degradation via the ubiquitin mediated proteosome pathway, however in response to 
cellular stress, such as DNA damage, there is stabilization, nuclear translocation, and 
accumulation of p53. This leads to transcriptional activation of various p53 target genes 
including those encoding p21WAF1, BAX, and MDM2, which can result in cell cycle 
arrest, differentiation, senescence or apoptosis.2
Unlike many other cancers, p53 is rarely mutated in neuroblastoma, occurring in 
only ~2% of cases analyzed to date, with the majority being described in refractory 
and relapsed neuroblastomas (reviewed in ref. 3). Consistent with this, we previously 
demonstrated that p53 was wild‑type in a cell line established at diagnosis, but had 
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developed a missense mutation at codon 135 in the cell line estab‑
lished from the same patient at relapse.4 Despite being wild‑type, 
p53 has been reported to accumulate in neuroblastoma, exhibiting 
enhanced stability.5 The presence of accumulated p53 in neuroblas‑
toma has been suggested to be due to the embryonic nature of these 
tumors, reflecting a failure of the precursor cells to mature.5 Early 
studies reported cytoplasmic sequestration of wild‑type p53 in undif‑
ferentiated neuroblastomas, where this phenotype was associated 
with a failure to G1 arrest following DNA damage, and thus cyto‑
plasmic sequestration was proposed as a non‑mutational mechanism 
for p53 inactivation and accumulation in neuroblastoma.6,7 Several 
mechanisms for cytoplasmic sequestration have been proposed, most 
recently due to hyperubiquitylation of p53.8 However, we and others 
have reported predominantly nuclear localization of p53 in neuro‑
blastoma cell lines and an intact downstream transcriptional response 
after DNA damage.9,10
Eizenberg et al. previously reported that p53 plays a regulatory 
role in the differentiation and apoptosis of central nervous system 
associated cells, where p53 levels and subcellular localization were 
found to change during maturation.11 In this study we hypothesized 
that p53 localization and function is dependent on the differentia‑
tion status of neuroblastoma and investigated this in neuroblastoma 
tumors and neuroblastoma cell lines undergoing retinoic acid induced 
differentiation.
MAteriALs And Methods
Tumors. Eighty‑two untreated neuroblastomas or ganglioneuro‑
blastomas were identified from the Northern Region Children’s and 
Young Person’s Malignant Disease Registry, and two mature ganglio‑
neuromas. One formalin‑fixed, paraffin‑embedded block with the 
most undifferentiated tumor present, was selected from each case, 
together with some surrounding normal tissue, if possible, to provide 
an internal control. From five of these cases frozen tissue was also 
studied by immunocytochemistry, and in five cases tumors were also 
analyzed by Western blotting. Twenty‑four pre‑ and post‑induction 
chemotherapy stage 3 and 4 neuroblastomas from patients diag‑
nosed between 1990 and 1999 were also studied. All patients had 
received standardized chemotherapy (seven courses of cisplatin based 
OPEC/OJEC12 or more dose intensive rapid COJEC, or CADO/
VPCarbo13). Surgery was undertaken around three weeks after the 
final course of chemotherapy if a bone marrow complete response, 
and at least a primary tumor partial response, had been obtained. 
Post‑chemotherapy tumors were carefully reviewed to ensure there 
was adequate neuroblastoma remaining using the NB84 antibody to 
demarcate residual tumor.
International neuroblastoma pathology classification (INPC). 
All untreated tumors were reviewed by two European Neuroblastoma 
Study Group histopathologists [S.V and C.C] and classified according 
to the INPC and the Shimada system.14 This involved classifying 
tumors as neuroblastoma (Schwannian stroma‑poor) or ganglioneu‑
roblastoma stroma‑rich (>50% Schwannian stroma). The latter are 
subdivided into nodular or intermixed. If nodular, the stroma‑poor 
nodule was classified along with other stroma‑poor neuroblastomas 
into International Neuroblastoma Classification (INC) undiffer‑
entiated, if neuropil was absent, and poorly differentiated or 
differentiating, if it was present. Poorly differentiated and differen‑
tiating tumors were distinguished by the % of cells with ganglionic 
differentiation. The % of cells with convincing neuronal differentia‑
tion was also quantified separately as 0%, <5%, or >5%. The Mitosis 
Karyorrhexis Index (MKI), an index of mitotic and apoptotic cells, 
was recorded as low (<100/5000 cells per high power field), interme‑
diate (100–200) or high (>200/5000). Calcification and the presence 
of anaplasia were also recorded. Tumors were classified as having 
unfavorable or favorable histology according to the Shimada and 
INPC systems of classification using previously published criteria 
including age, presence of Schwannian stroma, differentiation and 
MKI.14
Cell lines and retinoid treatment. Two p53 wild‑type neuro‑
blastoma cell lines established from untreated neuroblastomas at 
diagnosis were used in this study,15 MYCN amplified NBLW16 
and non‑MYCN amplified NB6917 were maintained in RPMI 
1640 (Sigma, St. Louis, MO) supplemented with 10% fetal bovine 
serum (Sigma), 100units/ml penicillin, and 100 mg/ml streptomycin 
(Sigma) in a 37°C, 5% CO2 humidified incubator. 9‑cis retinoic 
acid (RA) powder (Sigma) was dissolved in ethanol to 1mg/ml and 
diluted in cell culture medium prior to use to obtain final concentra‑
tions of 1 x 10‑6 M, with a maximum ethanol concentration of 0.1%. 
The culture medium was replaced every two days with fresh medium 
containing RA or control solvent. Cells were treated for a maximum 
of seven days. Cellular morphology in terms of neurite extension 
and length were captured using a Nikon COOLPIX 4500 camera 
attached to an Olympus LH50A inverted phase‑contrast microscope. 
Neurite length was measured from the photomicrographs using NIH 
image analysis software, Image J, available at rsb.info.nih.gov/ij/.
Immunocytochemistry (ICC). Three micrometer sections were 
cut from formalin‑fixed, paraffin‑embedded cell cytoblocks and 
tumors, and placed on adhesive‑coated (3‑aminopropyltriethoxysi‑
lane) (Sigma) microscope slides. ICC was also performed on cells 
cultured on Labtek™ chamber glass slides (Nunc, Naperville, 
IL) treated with either RA or control solvent for seven days. ICC 
was performed using the streptavidin‑biotin peroxidase technique 
(as previously described Ref. 9). Primary antibodies used were 
mouse monoclonal p53 DO‑7 (amino acids 20–25) at 1:50, p53 
Pab1801 (amino acids 46–55) at 1:40, Ki67 (MM1) 1:200, NB84 
1:200, Bcl2 1:50 (all NovoCastra, Newcastle upon Tyne, UK), p53 
DO‑1 (amino acids 20–25) hybridoma supernatant 1:4, p21WAF1 
1:50 (Calbiochem, Cambridge, MA), and rabbit polyclonal BAX 
antibody 1:250 (Santa Cruz, Los Angeles, CA). Secondary anti‑
bodies used were rabbit anti‑mouse biotinylated antibody 1:500 
(Dako, Glostrup, Denmark) and swine anti‑rabbit biotinylated 
antibody 1:1000 (Dako). Negative controls included incubations 
without primary antibodies and surrounding non‑tumor tissue. 
Specificity controls for p53 included Western blotting in five cases 
and antigen‑absorption controls in six cases. Antigen‑absorption 
controls were performed using a blocking peptide of ten amino 
acids to the p53 DO‑7 antibody (QETFSDLWKL) and a control 
unrelated peptide (glutathione S transferase) of 20 amino acids 
(TAGGWAAASDSRKGGEPAGY).
Tumor scoring. The Labeling Index (LI), % of immunostained 
cells, was determined by counting 1000 cells in the areas of densest 
immunostaining using an Olympus CX microscope at x 40 magni‑
fication. For BAX scoring, intensity was used as it produced diffuse 
cytoplasmic immunostaining of neuropil which made it difficult to 
determine which cell the staining originated from. This was graded 
as: 1, no staining; 2, mild; 3, moderate; and 4, intense staining. 
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Scoring of tumors was performed blind by independent observers, 
DT and KW or AJM. Concordance was reached in > 95% cases and 
any discrepancies were resolved by a consensus.
Statistical analysis. Minitab version 11.2 (Minitab Inc., PA,) 
statistical software was used for all Mann‑Whitney, Wilcoxon‑rank 
and c2 analyses. All statistical tests were 2 sided. Survival analysis was 
performed using the Kaplan‑Meier method, the Logrank test using 
Graph Pad Prism Software version 4.0, 2003 (CA), and multi‑variate 
analysis using forward and backward stepwise Cox regression in the 
Cox‑Proportional Hazards Model using SPSS version 11 (SPSS Inc, 
Chicago, IL) statistical software for Windows. Both progression 
free (PFS) and overall survival (OS) were studied, but not tumor 
response, as reliability of tumor size measurements could not be 
guaranteed in the older tumors. The OS was defined as the time in 
months between diagnosis and death or last follow up (excluding 
patients who died from toxicity), and the PFS was the date of diag‑
nosis to first detectable recurrence or progression, or the date of last 
follow up if progression had not occurred. Paired data was analyzed 
using the Wilcoxon signed rank test (Minitab) and for contingency 
tables McNemar’s test (SPSS). The level of statistical significance 
used was p < 0.05.
Indirect immunofluorescence (IF). Cells were cultured as for 
ICC. IF was performed and images captured (as previously described 
by Cowell et al., ref. 18). Primary antibodies used were mouse mono‑
clonal p53 DO‑1 (Calbiochem) 1:1000, neurofilament (Sigma) 
1:200, rabbit polyclonal p53 CM1 1:1000 and Alexa Fluor® 594 
goat anti‑mouse/rabbit IgG (Invitrogen) 1:200. The slides were 
mounted with coverslips using VectaShield® with DAPI (Vector 
Laboratories, Burlingame, CA). Negative controls included incuba‑
tions without primary antibodies.
Cell fractionation. Cells were separated into nuclear and cyto‑
plasmic fractions using the CelLytic™ Extraction Kit (Sigma). The 
samples were quantified and subjected to Western blot analysis as 
described below. To determine the integrity of the fractions, both 
control nuclear and cytoplasmic antibodies were included: TBP 
(TATA Binding Protein) (Abcam, Cambridge, UK) 1:1000 and 
porin (Invitrogen) 1:1000, respectively.
Irradiation induced DNA damage and Nutlin‑3 treatment. The 
undifferentiated and RA differentiated cells were treated with 4Gy 
X‑irradiation from a RS320 irradiation system (Gulmay Medical, 
Surrey, UK). Cells were harvested at 0, 2, 6 and 24 hours post irradia‑
tion for protein analysis. Nutlin‑3 (Cayman Chemical, Ann Arbor, 
MI) was dissolved in DMSO (Sigma) to a 10mM stock solution and 
diluted in cell culture medium prior to use. The undifferentiated 
and RA differentiated cells were treated with 10 mM or 20 mM of 
Nutlin‑3, or an equal volume of DMSO. Cells were harvested six 
hours after treatment for protein analysis.
Western blot analysis. Whole cells were lysed and Western 
blot analysis was performed using previously described methods.9 
Primary antibodies used were p53 DO‑7 (Novocastra) 1:1000, 
MYCN NCMII100 1:10, Bcl2 (Novocastra) 1:100, PARP (Santa 
Cruz) 1:1000, cleaved caspase 3 (New England Biolabs, Beverly, 
MA) 1:1000, b‑actin (Sigma) 1:500, MDM2 (Calbiochem) 1:100, 
and p21WAF1 (Calbiochem) 1:100. Secondary goat anti‑mouse/
rabbit HRP conjugated antibody (Dako) was used at 1:500. Protein 
detection was performed using enhanced chemiluminescence (GE 
Healthcare, Buckinghamshire, UK) (as previously described in 
ref. 9). Protein levels were quantified by densitometry analysis using 
a FUJI‑LAS‑3000 system and analyzed using the AIDA analyzer 
program (Raytek, Sheffield, UK).
resuLts
Neuroblastoma tumors. Eighty‑two untreated neuroblastoma 
and ganglioneuroblastoma tumors were studied, 7 (9%) stage 1, 11 
(13%) stage 2, 9 (11%) stage 3, 51 (62%) stage 4 and 4 (5%) stage 
4s tumors (International Neuroblastoma Staging System),19 and two 
ganglioneuromas. From 24 of these cases tumor was also studied 
post chemotherapy. Since tumors were obtained between 1968 and 
1999, during which time neuroblastoma treatment changed consid‑
erably, tumors were grouped according to year of diagnosis as follows: 
1968‑77, 1978‑87, 1988‑1999 (Table 1). In 1977 referral of neuro‑
blastomas to Newcastle for multiple modality treatment commenced 
and in 1987 dose‑intensive chemotherapy commenced.20 In this 
study, stage has been classified as: stage 1, 2 and 4s (low‑risk), stage 
3 and infant stage 4 (intermediate‑risk) and stage 4 over 1 year of 
age (high‑risk) (Table 1). Infants with stage 4 disease have a better 
prognosis than older children.21 Histopathological classification 
was attempted in 77 tumors; in five there was insufficient or inad‑
equate material and for some categories e.g., MKI, only 65 could 
be classified (Table 1). There was only one case classified differently 
between the Shimada and International Neuroblastoma Pathology 
Classification (INPC) systems, so in subsequent analyses only the 
INPC system was used. NB84, a neuroblastoma marker was positive 
in 79/81 (98%) tumors. Nine cases of undifferentiated neuroblas‑
toma were confirmed as neuroblastoma by a combination of raised 
urinary catecholamines, MYCN amplification and NB84 positivity. 
In the analyses poorly differentiated and differentiating tumors were 
combined, < 5% and > 5% neuronal differentiation were combined, 
and intermediate and high MKI tumors were combined. Since 
anaplasia was present in only three tumors this was excluded from 
further analysis.
p53 expression and localization. p53 expression detected by 
Western blotting was specific, and expressed at higher levels in a 
stage 4 poorly differentiated neuroblastoma than a stage 1, poorly 
differentiated neuroblastoma, two mature ganglioneuromas and 
a post‑treatment adrenal neuroblastoma (Fig. 1A). The presence 
of additional bands in the two mature ganglioneuromas are most 
likely to represent non‑specific bands rather than p53b or p53g 
isoforms despite being of approximately the correct molecular weight 
(46 kd) and detectable using the p53DO‑7 antibody which recog‑
nizes the N terminal.22 This is because this blot was originally probed 
for MDM2 when a 98kd protein could not be identified, but several 
lower molecular weight bands including the additional bands in the 
two mature ganglioneuromas were present (data not shown). The 
same blot was then reprobed for p53 (Fig. 1A). The p53b isoform 
has recently been reported in a p53 mutant neuroblastoma cell line.23 
The post treatment adrenal gland did not express p53 consistent 
with a previous study reporting that neuroblastomas overexpress p53 
relative to bovine adrenal medulla.5
Using three different p53 antibodies covering two separate N 
terminal epitopes, p53 was found to be predominantly nuclear in 
formalin fixed and frozen neuroblastoma (Figs. 1B, D and 2E). p53 
expression was heterogeneous within tumors and the percentage 
of cells with nuclear expression quantified using the LI. In cells 
showing increased differentiation towards ganglion cells (reduced 
nuclear to cytoplasmic ratio, increased neuropil, increased basophilic 
cytoplasm), some cytoplasmic p53 could be identified (Figs. 1E 
and 2B and E), particularly with the Pab1801 antibody. However, 
www.landesbioscience.com Cell Cycle 2687
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in some differentiating neuroblastoma cells, particularly those post 
chemotherapy, this cytoplasmic staining was also present in controls 
without primary antibody (Fig. 2A and D). Furthermore, compared 
with Bcl2, the p53 cytoplasmic immunostaining was much weaker 
(Fig. 2F). Using antigen‑absorption controls with a blocking peptide 
for the DO‑7 epitope, all the nuclear and some cytoplasmic staining 
were abrogated (Figs. 1G and 2G). Using an unrelated peptide, 
cytoplasmic p53 staining was abrogated and nuclear p53 staining 
was weaker, suggesting that the p53 antibody bound more strongly 
to nuclear p53 or the cytoplasmic staining was at least partly non‑
specific (Figs. 1H and 2H). The weak cytoplasmic p53 expression 
seen in the mature ganglioneuroma in Figure 2B is consistent with 
much lower levels of p53 expression by Western blotting compared 
with the other tumors in Figure 1A. In the subsequent analyses only 
nuclear p53 was scored.
Nuclear p53 accumulates in unfavorable neuroblastoma. 
The labeling indices (LI) for all antibodies for the untreated 
neuroblastomas are shown in Table 2. The median LI was chosen as a 
cut‑off between high (positive) and low (negative) expression, except 
for BAX where ≥ 3 + (moderate expression) was used as the cut‑off. 
p53 LIs detected by DO‑7 and DO‑1 antibodies were similar, but 
the Pab1801 LI was lower (Table 2). p53 expression detected by 
DO‑7 strongly correlated with expression detected by the other two 
p53 antibodies (DO‑7 v DO‑1 r = 0.85, DO‑7 v Pab1801 r = 0.74, 
DO‑1 v Pab1801 r = 0.74, Spearman correlation p < 0.0001) (data 
not shown). Seventeen out of 82 tumors were biopsied from a meta‑
static site other than bone marrow (Table 1). There was no significant 
difference between p53 or p53 regulated protein expression in 
tumors biopsied from either the primary site or a non‑bone marrow 
metastasis (data not shown). High p53 expression was associated with 
Table 1	 Clinical	and	pathological	characteristics	of	82	untreated	neuroblastomas
characteristic (n = number tested)  number %
Age (median age = 26 months) < 12 months 20 24
 ≥ 12 months 62 76
Stage risk groups 1, 2 and 4s (low) 22 27
 3 and infant stage 4 (intermediate) 18 22
 Stage 4 ≥ 12 months (high) 42 51
Year of diagnosis  1968-1977 21 26
  1978-1987 19 23
  1988-1999 42 51
Site of Primary tumor Abdominal 64 79
 Other 17 21
 Unknown 1 1
Site of pre-treatment biopsy (excluding bone marrow) Primary 65 80
 Metastatic site 17 20
MYCN amplification (n = 40)  11 29
Tumor type Stroma-poor neuroblastoma 73 89
 Stroma-rich ganglioneuroblastoma 9 11
 Intermixed ganglioneuroblastoma 3 4
 Nodular ganglioneuroblastoma 6 7
INPC (n = 77) Favorable 27 35
 Unfavorable 50 65
Shimada (n = 77) Favorable 28 36
 Unfavorable 49 64
INC (n =76) Undifferentiated 9 12
 Poorly differentiated 64 84
 Differentiating 3 4
% neuronal differentiation (n = 74) 0% 64 86
 < 5% 7 10
 > 5% 3 4
MKI (n = 65) Low 48 74
 Intermediate 12 18
 High 5 8
Calcification (n = 76) Present 15 20
Anaplasia (n = 74)     Present                 3             4
INPC, International Neuroblastoma Pathology Classification; INC, International neuroblastoma classification of differentiation; MKI, Mitosis Karyorrhexis Index.
2688 Cell Cycle 2007; Vol. 6 Issue 18
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intermediate and high risk neuroblastoma (Table 2 and Fig. 3A), and 
undifferentiated tumors defined by both the % of cells with neuronal 
differentiation and the international neuroblastoma classification of 
differentiation (INC) (Table 2 and Fig. 3B). In contrast Bcl2 LI was 
higher in INC Group 2 (poorly differentiated and differentiating 
neuroblastoma) than Group 1 (undifferentiated neuroblastoma) 
(Fig. 3C). High Ki67 expression, a proliferation marker, was associ‑
ated with high p53 expression (Table 2) and the labeling indices 
correlated (r = 0.51, p <0.0001) (Fig. 3D). p53 expression was asso‑
ciated with p21WAF1 expression by Chi‑squared analysis (Table 2), 
although the labeling indices only weakly correlated (r = 0.37, 
p < 0.001 DO‑1) (Fig. 3E).
At the time of analysis, 36 patients whose untreated tumors were 
studied were alive and 39 patients had died from disease. The median 
overall survival (OS) was 44 months (range 0–395) and progression 
free survival (PFS) 26 months (range 0–395). Using 
univariate logrank analysis, age ≥ 12 months, stage 
risk group, high p53 expression with all three 
antibodies, neuroblastoma type, INPC unfavor‑
able histology, 0% tumor cell differentiation, the 
absence of calcification and year of diagnosis were all 
adverse prognostic indicators for both PFS and OS 
(Fig. 3F and data not shown). Stage risk groups and 
year of diagnosis were the most significant prognostic 
markers p < 0.0001 for both OS and PFS.
Multivariate forward and backward stepwise Cox 
regression analysis for OS and PFS was carried out, 
including variables found to be statistically signifi‑
cant on univariate analysis at ≤ 5%. As each variable 
was considered in the regression analysis of OS and 
PFS and then either added or removed, only stage 
(1, 2 and 4s‑low and 3 and 4‑high) and year of 
diagnosis remained significant. This was also the case 
when p53 LI was considered as a continuous variable 
(data not shown).
In the paired pre and post chemotherapy neuro‑
blastomas there was a significant reduction in the p53 LI, as well as 
p21WAF1 and Ki67, in tumors post‑chemotherapy compared with 
untreated tumors (Suppl. Table 1A), and a significant increase in the 
proportion of tumors immunostaining positive for BAX post‑chemo‑
therapy (Suppl. Table 1B). There was no change in Bcl2 LI between 
pre and post‑chemotherapy tumors (Suppl. Table 1A).
Cell lines. Retinoic acid induced differentiation. To induce 
differentiation, NB69 non‑MYCN amplified and NBLW MYCN 
amplified neuroblastoma cell lines were treated with 1mM RA 
and the onset of differentiation was monitored by neurite exten‑
sion (Fig. 4A). Additionally, using light microscopy,0 a decrease in 
proliferation was observed. Cellular differentiation was defined by 
the presence of neurites at least twice the length of the cell body. 
Three differentiation markers; neurofilament, synaptophysin and 
tyrosine hydroxylase were also used to confirm differentiation by 
Figure 1. (A) Western blots of neuroblastic tumors. 1 = 
Stage 4, stroma-poor, poorly differentiated neuroblastoma 
shown in B-D, 2 = Stage 1, stroma-poor, poorly differenti-
ated neuroblastoma shown in E-H, 3 and 4 = Mature gan-
glioneuromas, 5 = Post-treatment adrenal gland, IMR32 = 
Control IMR32 cell lysate 6 hours after 4Gy irradiation. 
(B) Nuclear p53DO-7 immunostaining in a formalin-fixed, 
paraffin-embedded neuroblastoma (Tumor 1) showing 
heterogeneous nuclear immunostaining (brown) with nega-
tive mitotic cells (arrowed). (C and D) Frozen sections of 
same tumor as B. (C) is a control without primary antibody 
showing absence of background staining. (D) is p53 DO-7 
immunostaining showing predominantly nuclear immunos-
taining. E-H = Tumor 2. (E) Mixed nuclear and cytoplasmic 
p53DO-7 immunostaining (arrowed) in formalin-fixed, 
paraffin-embedded neuroblastoma. (F) Control without 
primary antibody. (G) Antigen-absorption control showing 
complete abrogation of nuclear and partial abrogation of 
cytoplasmic staining (arrowed) with a DO-7 epitope-spe-
cific peptide. (H) Antigen-absorption control with an 
unrelated peptide showing some nuclear (arrowed) but no 
cytoplasmic staining. Mitotic cells are negative (arrowed). 
Scale bar = 50 mM
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Western blot and immunofluorescence. Western analysis found that 
none of the tested differentiation markers were consistently upregu‑
lated despite obvious morphological differentiation, suggesting 
that there is a redistribution of differentiation markers rather than 
upregulation of expression (data not shown).
p53, Bcl2 and MYCN expression after differentiation. The 
protein levels of p53 and Bcl2 were examined in undifferenti‑
ated and RA differentiated NB69 and NBLW cells, and MYCN 
in MYCN amplified NBLW cells. Following differentiation, p53 
levels decreased in NB69 cells (Fig. 4B(ii)), but not in NBLW cells 
(Fig. 4B(i)) (as previously reported, refs. 5 and 24) and supports 
the earlier observation of higher p53 expression by ICC in undif‑
ferentiated neuroblastoma (Table 2 and Fig. 3B). MYCN levels 
in NBLW cells decreased following differentiation (Fig. 4B(i)) 
consistent with previous reports in MYCN amplified 
cells.25 Bcl2 levels increased after differentiation in 
both cell lines (Fig. 4B), consistent with (previous 
reports, refs. 26–28) and the earlier observation of 
increased Bcl2 expression in poorly differentiated 
and differentiating neuroblastomas compared with 
undifferentiated tumors (Fig. 3C).
p53 localization in undifferentiated and differ‑
entiated neuroblastoma cell lines. Both ICC and 
IF were used to immunolocalize p53 within cells. 
p53 was found to be predominantly nuclear in 
both undifferentiated and differentiated NB69 and 
NBLW cells using two different p53 antibodies 
(Fig. 5C, D and F). The negative controls gave 
expected results. To confirm the results of ICC and 
IF, cell fractionation was performed (Fig. 6A). This 
showed predominantly nuclear p53 in both undif‑
ferentiated and differentiated NB69 and NBLW 
cells, confirming the results of ICC and IF. In addi‑
tion lower levels of nuclear p53 were observed in 
NB69 cells after retinoic acid induced differentiation 
(Fig. 6A(ii)) consistent with the results shown in 
Figure 4B(ii) for this cell line.
p53 function in response to irradiation and 
Nutlin‑3 treatment in undifferentiated and differ‑
entiated neuroblastoma cells. p53 transcriptional 
function was assessed in response to irradiation 
induced DNA damage using Western blotting to measure induction 
of p53 and p53 responsive genes encoding MDM2 and p21WAF1. 
After irradiation, p53 was stabilized in both undifferentiated and 
differentiated NB69 and NBLW cells by two hours and sustained 
until 24 hours (Fig. 6B). Similarly, MDM2 and p21WAF1, the 
products of p53 responsive genes, were induced in both cell lines. 
Induction of MDM2 occurred maximally at six hours after irra‑
diation, and induction of p21WAF1 occurred by two hours and was 
sustained until 24 hours. A higher basal level of p21WAF1 expression 
was observed in differentiated cells of both cell lines compared to 
undifferentiated control cells (Fig. 6B), consistent with previous 
reports.29
Induction of apoptosis was assessed by Western blotting to detect 
cleaved PARP and cleaved caspase 3 as early markers of apoptosis. 
Figure 2. (A and B) Mature ganglioneuroma, Tumor 
3 in Figure 1A. (A) Control without primary antibody 
showing very weak background cytoplasmic staining in 
ganglion cells but not Schwannian stroma. (B) p53DO-7 
showing weak cytoplasmic staining in ganglion cells. 
(C–H) Post-chemotherapy, stage 4, primary neuroblastoma. 
(C) Hematoxylin and Eosin stain showing neuroblastoma 
cells at varying stages of differentiation. (D) Control with-
out primary antibody showing weak background cyto-
plasmic staining in differentiating neuroblastoma cells. 
(E) p53DO-7 showing nuclear and cytoplasmic staining 
(arrowed) with a negative apoptotic cell (arrowed). (F) 
Strong Bcl2 cytoplasmic immunostaining. (G) Antigen 
absorption control with a DO-7 epitope-specific peptide 
showing abrogation of all nuclear and most cytoplasmic 
staining. (H) Antigen-absorption control with an unrelated 
peptide showing some nuclear, but no cytoplasmic stain-
ing. Scale bar = 50 mM.
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p53 Localization in Neuroblastoma Tumors and Cell Lines
Cleavage of PARP and caspase 3 was evident six hours post irradia‑
tion in both undifferentiated NBLW and NB69 cells, but there was 
minimal evidence of cleaved PARP or caspase 3 in differentiated cells 
(Fig. 6B). This is consistent with previous reports showing resistance 
to cytotoxic agents after retinoic acid induced differentiation.26,28,30
Nutlin‑3 is a potent and selective small‑molecule antagonist of 
the MDM2‑p53 interaction, which results in stabilization of p53 
and induced expression of p53 target genes in cells with wild‑type 
functional p53.31 To provide further evidence that p53 is functional 
in undifferentiated and differentiated NB69 and NBLW cells, cells 
were treated with Nutlin‑3 or DMSO vehicle control for 6 hours. 
Induction of p53 and p53 target genes, p21WAF1 and MDM2 was 
observed in both undifferentiated and differentiated cells after treat‑
ment with 10mM or 20mM of Nutlin‑3 compared to cells treated 
with DMSO (Fig. 6C), and further confirms that p53 is functional, 
and transcriptionally active after differentiation. Again, a higher basal 
level of p21WAF1 expression was observed in differentiated cells of 
both cell lines compared to undifferentiated control cells (Fig. 6C), 
consistent with the data in Figure 6B and also previous reports.29
discussion
The prognosis for children with high‑risk neuroblastoma (stage 
4 disease over one year of age, or localized or infant neuroblas‑
toma with MYCN amplification) remains poor with <30% long 
term survival. Although p53 mutations have been found in a small 
proportion (~2%) of untreated neuroblastomas at diagnosis, p53 
cellular localization and function in neuroblastoma are still contro‑
versial areas of research. We examined p53 localization and mediators 
of p53 function in a panel of 82 untreated neuroblastoma and 
ganglioneuroblastoma tumors which were a representative, 
unselected sample comprising 60% stage 4 disease and a median 
age at presentation of 26 months, consistent with previous large 
surveys.32 In addition we examined p53 localization and mediators 
of its function in a subset of 24 paired pre and post chemotherapy 
neuroblastomas.
p53 immunostaining was found to be predominantly nuclear 
in both formalin‑fixed and frozen neuroblastomas consistent with 
previous studies on formalin‑fixed material,33‑36 but not a single 
study of frozen neuroblastoma, in which predominantly cytoplasmic 
p53 was reported in undifferentiated neuroblastoma using the same 
p53 antibodies.6 Using the median LI as a cut‑off between high and 
low expression, the current study found high nuclear p53 expression 
to be associated with INPC undifferentiated neuroblastoma, and 
both nuclear and cytoplasmic p53 immunostaining was observed in 
differentiating neuroblastoma using all three antibodies, particularly 
Pab1801. Nuclear and some cytoplasmic staining was abrogated 
using a specific peptide antigen‑absorption control, and the cyto‑
plasmic, but not the nuclear staining, was also abrogated by an 
unrelated peptide control, suggesting that either the antibody binds 
more strongly to nuclear p53, or the cytoplasmic staining is at least 
partially non‑specific. However, it is likely that some cytoplasmic 
Table 2	 Relationship	between	p53	and	stage,	histopathology,	Ki67,	p21WAF1,	BAX	and	Bcl2	expression	
	 in	82	untreated	neuroblastomas
 n = p53do‑7 8% (0,75)* p53do‑1 7% (0,89)* p53Pab1801 2%(0,20)* 
   ‑ + p ‑ + p ‑ + p
Stage Risk Gp 
Low 22  19 3 < 0.001 19 3 < 0.001 21 1 <0.001 
Intermediate 18  8 10  7 11  8 10  
High 42  14 28  13 28  19 23 
INPC 77 FH 18 9 0.06 17 10 0.07 18 9 0.4 
  UH 22 28  20 29  28 22 
Diff% 74 1 26 38 < 0.05 25 38 0.07 32 32 < 0.05 
  2 8 2  7 3  9 1 
INC 76 1 0 9 < 0.01 0 9 < 0.01 0 9 < 0.001 
  2 36 31  34 32  43 24 
MKI 65 1 27 21 0.06 24 24 0.3 30 18 0.3 
  2 5 12  6 11  8 9 
Calcifn 76 - 25 26 < 0.05 26 35 0.3 30 31 < 0.01 
  + 11 4  8 6  13 2 
Ki67 20% (0,86)* 82 - 27 14 < 0.01 27 13 < 0.01 32 9 < 0.001 
  + 14 27  12 29  16 25 
p21 2% (0,25)* 81 - 29 17 < 0.01 27 18 < 0.05 34 12 < 0.01 
  + 11 24  11 24  13 22 
BAX ≥3+ 82 - 26 29 0.5 24 30 0.4 31 24 0.6 
  + 15 12  15 12  17 10 
Bcl2 63% (2,98)* 82 - 20 19 0.8 21 17 0.2 24 15 0.6 
  + 21 22  18 25  24 19 
*Median labeling index % (range = lowest and highest values recorded) for each of the antibodies studied. The median labeling index was used as cut-off between positive and negative expression, except for BAX 
where ≥ 3 + (moderate expression) was used as the cut‑off. All comparisons c2 used. FH, Favorable Histology; UH, Unfavorable Histology, (INPC classification). Diff %, Differentiating %; 1 = 0; 2 = >0 %; INC 1 
= undifferentiated; 2 = poorly differentiated and differentiating. MKI 1 = low; 2 = intermediate and high; Calcifn, Calcification.
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p53 does exist in neuroblastoma, as nuclear localization sequences 
for both p53 nuclear import and export exist,37 a cytoplasmic 
anchor for p53 has been identified, Parc,38 and a role for mitochon‑
drial associated p53 in inducing apoptosis has been proposed.39 
In an immunohistochemical study of neuroblastoma tumors by 
Douc‑Rasy et al., the subcellular distribution and staining intensity of 
p73, a member of the p53 family, varied with the amount of neuronal 
differentiation and there was a redistribution of p73 from the nucleus 
to the cytoplasm during neuroblastic differentiation.40 Additionally, 
Eizenberg et al found that during maturation of primary oligoden‑
drocytes and neurons, the subcellular localization of p53 changes 
from being predominantly in the nucleus during differentiation to 
predominantly cytoplasmic in fully mature cells p53.11 Due to the 
structural and partial functional homology between p73 and p53, 
and the observations in primary oligodendrocytes and neurons,11 
it is possible there may be a redistribution of p53 following differen‑
tiation of neuroblastoma cells.
To further investigate this we examined p53 localization and 
function in a p53 wild‑type MYCN amplified and a non‑MYCN 
amplified cell line undergoing RA induced differentiation. To date 
no study has investigated the localization of p53 in neuroblas‑
toma cell lines undergoing differentiation. We found p53 to be 
p53 Localization in Neuroblastoma Tumors and Cell Lines
Figure 3. p53 LI refers to nuclear p53 only. Median shown on scatter-plots. (A) p53DO-1 LI v stage risk group 1 = Low = stage 1, 2 and 4s, 2 = Intermediate 
= stage 3 and infant stage 4, 3 = High = stage 4 over 1 year of age (Kruskall-Wallis test). (B) p53Pab1801LI v INC = International Neuroblastoma 
Classification of Differentiation, Gp1 = Group 1 undifferentiated, Gp2 = Group 2 poorly differentiated and differentiating (Mann-Whitney test). Median 
difference shown and 95% Confidence Interval. (C) Bcl2 LI v INC (Mann-Whitney test). Median difference shown and 95% Confidence Interval. 
(D) p53Pab1801 LI v Ki67 LI (Spearman correlation and 95% Confidence Interval). (E) p21LI v p53DO-1LI (Spearman correlation and 95% Confidence 
Interval). (F) Progression free survival for 75 neuroblastoma patients according to p53 DO-7 expression (p53 +ve ≥ 8% LI).
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predominantly nuclear in both undifferentiated and RA differenti‑
ated cell lines and there was no redistribution following retinoic acid 
induced differentiation.
In contrast to some previous studies,6,41 the evidence presented 
here suggests that p53 is predominantly nuclear in both neuro‑
blastoma tumors and cell lines before and after differentiation, 
particularly as some cytoplasmic p53 staining observed in differen‑
tiating neuroblastoma tumors was non‑specific. The observation of 
higher p53 expression in undifferentiated, Ki67 expressing tumors is 
consistent with results in NB69 cells showing higher levels of p53 in 
undifferentiated cells compared with differentiated cells.
To determine whether nuclear p53 is transcriptionally active in 
untreated neuroblastoma we measured expression of two proteins 
that p53 transcriptionally upregulates, p21WAF1 and BAX, together 
with one it may transcriptionally repress, Bcl2. In this series of 
neuroblastomas p53 expression was found to correlate weakly with 
p21WAF1 expression, but not Bcl2 or BAX. There is evidence to 
suggest that p53’s transcriptional function is best assessed by MDM2 
and p21WAF1 upregulation, as induction of BAX is dependent on cell 
type.2 However, evaluation of two different MDM2 antibodies on 
formalin‑fixed, paraffin‑embedded tumor samples proved unsatisfac‑
tory for ICC.
Comparing paired pre and post‑chemotherapy neuroblastoma, 
we observed a reduction in nuclear p53, Ki67 and p21WAF1 and an 
increase in BAX, suggesting selective killing of p53 expressing cells 
by chemotherapy. It is possible an increase in p53 and p21WAF1 
expression occurred initially after chemotherapy, as upregulation 
of p53, p21WAF1 and MDM2 was detectable six hours after ex‑vivo 
irradiation of one of the diagnostic, untreated paired tumors,9 but 
a sustained increase in p53 and p53 regulated protein expression 
persisting until the time of surgical resection three weeks after the 
final course of chemotherapy would not be expected. It is interesting 
that BAX expression increased in post‑chemotherapy tumors, which 
may be a delayed effect of p53 activation. In the ex‑vivo tumor 
described above, BAX expression was unchanged six hours after 
irradiation.9
Increased BAX expression, reduced Ki67, increased apoptotic 
index and unchanged p53 levels have been reported in locally 
advanced colorectal cancers studied before and two weeks after radio‑
therapy and chemotherapy.42 In paired non‑metastatic rectal tumors 
investigated pre and post‑radiochemotherapy, there was no change 
in p53 or BAX levels, but a reduction in p21WAF1 and Ki67, and 
patients with a decrease in p21WAF1 or an increase in Ki67 expression 
had improved survival.43 In the current study all except one of the 
p53 Localization in Neuroblastoma Tumors and Cell Lines
Figure 4. (A) Morphology of NBLW and NB69 cells after seven days of treatment with 1 mM 9cisRA or control solvent. The induction of differentiation is 
evident by the extension of neurites. (B) Western analysis for expression of p53, Bcl2 and MYCN in undifferentiated (C) and RA differentiated (RA) (i) NBLW 
and (ii) NB69 cells.
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paired pre and post chemotherapy cases responded to chemotherapy, 
with at least a partial response at the primary site, consistent with a 
functioning p53 pathway at diagnosis.
We also investigated p53 function after differentiation measured 
by transcriptional activity and induction of apoptosis in neuroblas‑
toma cell lines. We showed that p53 is functional after DNA damage 
in undifferentiated and differentiated NB69 and NBLW cells, as 
evident by p53 stabilization and the induction of p53 responsive 
genes encoding MDM2, and p21WAF1. Additionally, treatment of 
undifferentiated and differentiated NB69 and NBLW cells with 
Nutlin‑3, a specific p53‑MDM2 antagonist, showed stabilization 
of p53 and induced expression of p21WAF1 and MDM2, providing 
Figure 5. Immunofluorescent (A–D) and immunocytochemical (E and F) analysis of NBLW and NB69 cells. (A and E) No primary controls (NP) were incuba-
tions without primary antibody. (B) Immunostaining against neurofilament (NF) highlights the morphology and neurite extensions present in RA differentiated 
cells (RA) compared with undifferentiated control cells (Con). (C and D) show predominantly nuclear p53 in both undifferentiated and differentiated neuro-
blastoma cells using IF and ICC (F).
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confirmatory evidence of intact p53 function after differentiation. 
Consistent with previous studies we observed a reduction in irradia‑
tion induced apoptosis in differentiated cells.28,30 In contrast to the 
study by Ronca et al who proposed that retinoic acid confers resis‑
tance to chemotherapeutic agents by modulating nuclear import of 
p53,30 the present study shows that after irradiation induced DNA 
damage in differentiated neuroblastoma cell lines, there is nuclear 
translocation of p53, and the induction of p53 responsive genes 
encoding MDM2 and p21WAF1. This is despite a lower level of apop‑
tosis, suggesting the latter may be p53 independent in differentiated 
neuroblastoma, possibly by involving effects on apoptotic pathways 
downstream of p53.
This study is the first to investigate p53 localization in cell lines 
undergoing RA induced differentiation, and also in such a large 
series of neuroblastomas, which included both formalin‑fixed and 
frozen tumors. The results of the present study show that aber‑
rant cytoplasmic localization is uncommon in undifferentiated and 
differentiated neuroblastoma, and is unlikely to be an important 
mechanism of p53 inactivation in this tumor. The presence of tran‑
scriptionally active nuclear p53 in differentiating neuroblastoma cell 
lines suggests that mechanisms other than inactivation of the p53 
pathway, makes these cells more resistant to apoptosis.
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